Company news
Shandong Buchang Pharmaceuticals Co., Ltd. Class A (SSE:603858) news
Shandong Buchang Pharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (603858)"Shandong Buchang Pharmaceuticals Co.…
Press releases & updates
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Signing of Technology Transfer Contract by Wholly-owned Subsidiary
September 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Resolutions of the 57th Meeting of the 5th Board of Directors
September 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Proposed External Investment by Controlled Subsidiary for Establishment of Wholly-owned Subsidiary
September 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Cooperative Investment with Private Fund
September 29, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Capital Increase and Share Expansion of Controlled Subsidiary for Introduction of External Investors, the Company's Waiver of Preemptive Subscription Rights, and Related Party Transactions
September 29, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd"Announcement on Providing Guarantee for Controlled Subsidiary
September 28, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Proposed Capital Increase in Controlled Subsidiary
September 27, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Change of Legal Representative of Controlled Subsidiary
September 27, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Resolutions of the 56th Meeting of the 5th Board of Directors
September 27, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 16, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Completion of Industrial and Commercial Registration Change by Controlled Subsidiary
September 10, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Wholly‑owned Subsidiary
August 28, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Semi-annual Report for 2026
August 27, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Progress of Proposed Capital Increase to Controlled Subsidiary
August 24, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Signing of Supplementary Agreement to (Entrusted) Technical Service Contract by a Controlled Subsidiary
August 21, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Completion of Industrial and Commercial Registration Change by the Controlled Subsidiary
August 19, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Receipt of Acceptance Notice for Drug Clinical Trial by Controlled Subsidiary
August 17, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Change of Legal Representative of Controlled Subsidiary
August 11, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Progress in Proposed External Investment for Establishment of a Subsidiary
August 5, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Completion of Industrial and Commercial Change Registration by Wholly-owned Subsidiary
August 3, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Withdrawal of Drug Registration Application by Controlled Subsidiary
July 29, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Proposed External Investment for Establishment of a Subsidiary
July 28, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Change of Drug Production License of Wholly-owned Subsidiary
July 24, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Signing of (Entrusted) Technology Development Contract by Wholly-owned Subsidiary
July 23, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on the Proposed Capital Increase in a Controlled Subsidiary
July 21, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on the Completion of Registration of Change in Medical Device Business License by a Controlled Subsidiary
July 16, 2026
"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on the Adjustment of the Company's Products in the "National Essential Medicines List"
July 10, 2026
Announcement on Resolutions of the 51st Meeting of the 5th Board of Directors
June 29, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 26, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
June 22, 2026
Announcement on Progress in on Proposed Capital Increase in Holding Subsidiary and Change in Name of Holding Subsidiary
June 18, 2026
Announcement on Completion of Registration of Change in Business License for Medical Device by the Holding Subsidiary
June 10, 2026
Announcement on Progress in Holding Subsidiary's Proposal to Invest in the Establishment of a External Subsidiary
June 9, 2026
Announcement on Change of Drug Production License of Wholly-owned Subsidiary
June 8, 2026
Announcement on Initially Repurchasing Shares through Call Auction
June 2, 2026
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Limit Concerning Repurchase
June 1, 2026
Announcement on Progress in Proposed Transfer of Equity in a Holding Subsidiary and Waiver of the Right of First Refusal
May 29, 2026
Announcement on Providing Guarantee for Holding Subsidiary
May 28, 2026
Announcement on Providing Guarantee for Wholly-owned Subsidiary
May 26, 2026
Announcement on the Change of Business Scope of Wholly-owned Subsidiary
May 25, 2026
Announcement on Progress in Holding Subsidiary's Proposed Signing of Intellectual Property Cooperation Agreement
May 19, 2026
Announcement on the Change of Domicile of Holding Subsidiary
May 14, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Shandong Jurisdiction
May 13, 2026
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
May 12, 2026
Announcement on Progress in the Proposed Transfer of Holding Subsidiary Equity
May 11, 2026
Announcement on Receipt by its Holding Subsidiary of the Notice of Grant for the 2026 Project under the National Science and Technology Major Project for Prevention and Control of Emerging, Re-emerging and Major Infectious Diseases
May 8, 2026
Announcement on Change of Drug Production License of the Company and Wholly-owned Subsidiary
April 28, 2026
Announcement on 2025 Final Profit Distribution and Requesting the General Meeting of Shareholders to Authorize the Board of Directors to Prepare the 2026 Interim Dividend Plan
April 27, 2026
Announcement on Obtaining Malaysian Drug Registration Certificate for Yangzhengheji Decoction
April 8, 2026
Announcement on Resolutions of the 46th Meeting of the 5th Board of Directors
April 7, 2026